

# **Justification Document for the Selection of a CoRAP Substance**

Substance Name (public name): 3-({[(4-methylphenyl)sulfonyl]carbamoyl} amino)phenyl 4-methylbenzenesulfonate

EC Number: 432-520-2

**CAS Number:** 232938-43-1

**Authority:** BE CA

**Date:** 19/03/2019

#### **Cover Note**

This document has been prepared by the evaluating Member State given in the CoRAP update.

## **Table of Contents**

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
1.2	Similar substances/grouping possibilities	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3. 3.	Classification 1.1 Harmonised Classification in Annex VI of the CLP 1.2 Self classification 1.3 Proposal for Harmonised Classification in Annex VI of the CLP	<b>5</b> 5 5
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	5
4.1	Tonnage and registration status	6
4.2	Overview of uses	6
	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATION SUBSTANCE	E 7
5.1.	Legal basis for the proposal	7
	Selection criteria met (why the substance qualifies for being in AP)	7
5.3. Eva	Initial grounds for concern to be clarified under Substance luation	7
	Preliminary indication of information that may need to be uested to clarify the concern	8
5 5	Potential follow-up and link to risk management	8

## 1 IDENTITY OF THE SUBSTANCE

#### 1.1 Other identifiers of the substance

**Table: Other Substance identifiers** 

EC name (public):	3-({[(4-methylphenyl)sulfonyl]carbamoyl}amino)phenyl 4-methylbenzenesulfonate		
IUPAC name (public):	3-{[(4-methylbenzenesulfonyl)carbamoyl]amino}phenyl 4-methylbenzene-1-sulfonate		
Index number in Annex VI of the CLP Regulation:	006-099-00-7		
Molecular formula:	$C_{21}H_{20}N_2O_6S_2$		
Molecular weight or molecular weight range:	460.52		
Synonyms:	<ul> <li>Benzenesulfonamide, 4-methyl-N-[[[3-[[(4-methylphenyl)sulfonyl]oxy]phenyl]amino] carbonyl]-</li> <li>N-(p-toluenesulfonyl)-N'-(3-(p-toluenesulfonyloxy)phenyl)urea</li> <li>DP 201</li> <li>Pergafast 201</li> </ul>		

Type of substance	☐ Multi-constituent	☐ UVCB

#### Structural formula:

### 1.2 Similar substances/grouping possibilities

NA

## **2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION**

## **Table: Completed or ongoing processes**

RMOA	☐ Risk Management Option Analysis (RMOA)				
		☐ Compliance check			
	Evaluation	☐ Testing proposal			
REACH		☐ CoRAP and Substance Evaluation			
Processes	Akla a.via a.kia a	☐ Candidate List			
	Authorisation	☐ Annex XIV			
	Restriction	☐ Annex XVII¹			
CLH	☐ Annex VI (0	CLP) (see section 3.1)			
	☐ Plant Prote	☐ Plant Protection Products Regulation			
Processes under other	Regulation (EC) No 1107/2009				
EU legislation	☐ Biocidal Product Regulation				
	Regulation (EU) 528/2012 and amendments				
Previous	☐ Dangerous substances Directive 67/548/EEC (NONS)				
legislation	☐ Existing Substances Regulation 793/93/EEC (RAR/RRS)				
(UNEP) Stockholm	☐ Assessment				
convention (POPs Protocol)	☐ In relevant Annex				
Other processes/ EU legislation	☐ Other (provide further details below)				
Further details					

EC no 432-520-2 MSCA - Belgium Page 4 of 8

<sup>&</sup>lt;sup>1</sup> Please specify the relevant entry.

## 3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

#### 3.1 Classification

#### 3.1.1 Harmonised Classification in Annex VI of the CLP

**Table: Harmonised classification** 

Index No	International Chemical Identification	EC No	CAS No	Classifica	ation	Spec. Conc. Limits,	Notes
				Hazard Class and Category Code(s)	Hazard statement code(s)	M- factors	
006-099- 00-7	N-(p- toluenesulfonyl) -N'-(3-(p- toluenesulfonyl oxy)phenyl)ure a 3-({[(4- methylphenyl)s ulfonyl]carbam oyl}amino)phen yl 4- methylbenzene sulfonate	432- 520-2	232938- 43-1	Aquatic Chronic 2	H411		

#### 3.1.2 Self classification

• In the registration:

Same as the harmonized classification

 The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

NA

#### 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

NA

## 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES<sup>2</sup>

### 4.1 Tonnage and registration status

Table: Tonnage and registration status\*

☑ Full registration(s) (Art. 10)		$\square$ Intermediate registration(s) (Art. 17 and/or 18)				
Tonnage band (as per disseminat	Tonnage band (as per dissemination site)					
□ 1 – 10 tpa		10 - 100 tpa	□ 100 - 1000 tpa			
□ 1000 – 10,000 tpa		10,000 – 100,000 tpa	□ 100,000 - 1,000,000 tpa			
□ 1,000,000 - 10,000,000 tpa	□ 10,000,000 - 100,000,000 tpa		□ > 100,000,000 tpa			
⊠ 100 + tpa			⊠ Confidential			
One full registration dossier + one NONS registration						
* The total tonnage band has been calculated from information on the ECHA dissemination site by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11): <a href="https://echa.europa.eu/documents/10162/22308542/manual dissemination en.pdf/7e0b87c22681-4380-8389-cd655569d9f0">https://echa.europa.eu/documents/10162/22308542/manual dissemination en.pdf/7e0b87c22681-4380-8389-cd655569d9f0</a>						
4.2 Overview of uses						

**Table: Uses** 

D	-	•	•	1	
Г	a	•	L	_	•

	$\boxtimes$	$\boxtimes$	$\boxtimes$	$\boxtimes$	⊠ Article	☐ Closed
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system
		use	use	use		

#### Part 2:

<del></del>	
	Use(s)
Uses as intermediate	
Formulation	Formulation into mixture
Uses at industrial sites	Manufacture of thermal paper and thermal paper products
Uses by professional workers	Professional use of thermal paper and thermal paper products
Consumer Uses	Consumer use of thermal paper and thermal paper products
Article service life	Thermal paper and thermal paper products

EC no 432-520-2 MSCA - Belgium Page 6 of 8

<sup>&</sup>lt;sup>2</sup> Dissemination website consulted on 29 May 2018

## 5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

5.1.	Legal basis for the proposal
	oximes Article 44(2) (refined prioritisation criteria for substance evaluation)
	☐ Article 45(5) (Member State priority)
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)
	☑ Fulfils criteria as CMR/ Suspected CMR
	$\square$ Fulfils criteria as Sensitiser/ Suspected sensitiser
	oxtimes Fulfils criteria as potential endocrine disrupter
	☐ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
	$\square$ Fulfils criteria high (aggregated) tonnage ( $tpa > 1000$ )
	□ Fulfils exposure criteria
	$\square$ Fulfils MS's (national) priorities

## 5.3. Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns						
CMR □ C □ M □ R	Suspected CMR <sup>1</sup> □ C □ M ⊠ R	□ Potential endocrine disruptor				
☐ Sensitiser	☐ Suspected Sensitiser³					
☐ PBT/vPvB	☐ Suspected PBT/vPvB¹	☐ Other (please specify below)				
Exposure/risk based concerns						
☐ Wide dispersive use	☐ Consumer use	☐ Exposure of sensitive populations				
☐ Exposure of environment	☐ Exposure of workers	☐ Cumulative exposure				
☐ High RCR	☐ High (aggregated) tonnage	☐ Other (please specify below)				

<u>Suspected PBT</u>: Potentially Persistent, Bioaccumulative and Toxic

<sup>&</sup>lt;sup>3</sup> <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

- Reproductive toxicity: effects on testes were observed in the 28d short term toxicity study but not confirmed by the screening repro/developmental study. However, the latter study was only tested up to 200 mg/kg bw/d.
- Neurotoxicity: some changes were observed during neuro examination (locomotor activity) in the 28d short term toxicity study.
- Immunotoxicity: 28d and 90d study: changes in spleen and adrenal glands,
   28d study: changes in thymus.
- ED: in a study similar to OECD 455 (Stable Transfected Human Estrogen Receptor & Transcriptional Activation Assay for Detection of Estrogen Agonistic-Activity of Chemicals) the substance is suggested to be non-estrogenic with a relative potency substantially low compared to 17b-estradiol (10<sup>7</sup> times less potent). However an increase in luciferase activity (marker of ERa induction) was observed.

In a literature study on the endocrine activity of alternatives to BPA found in thermal paper in Switzerland (D.M. Goldinger et al, 2015) the substance was found to be non-estrogenic but a significant decrease in free testosterone level was observed although not dose-dependent and near background level. Furthermore PPAR $\gamma$  binding activity was positive (22.0 $\mu$ M - VirtualToxLab<sup>TM</sup>). Authors concluded that further studies are required to show that there are no adverse effects on the hormonal system.

#### Reference

Goldinger D.M., Demierre A-L., Zoller O., Rupp H., Reinhard H., Magnin R., Becker T.W., Bourqui-Pittet M. (2015) Endocrine activity of alternatives to BPA found in thermal paper in Switzerland. Regulatory Toxicology and Pharmacology, 71, 453-462.

## **5.4.** Preliminary indication of information that may need to be requested to clarify the concern

☑ Information on to	xicological properties	☐ Information of properties	☐ Information on physico-chemical properties				
$\square$ Information on fa	te and behaviour	☐ Information o	$\square$ Information on exposure				
$\square$ Information on eq	otoxicological propertie	s 🗆 Information o	n uses				
☑ Information ED po	otential	☐ Other (provid below)	☐ Other (provide further details below)				
•	A potential outcome of this evaluation could be the request of an EOGRTS to confirm the ED and repro concerns.						
5.5. Potential follow-up and link to risk management							
$oxed{\boxtimes}$ Harmonised C&L $oxed{\square}$ Restriction $oxed{\boxtimes}$ Authorisation $oxed{\square}$ Other (provide further details)							
Depending on the outcome of the evaluation, a proposal for harmonized C&L and/or SVHC identification could be envisaged.							